Targeted NGS analysis performed at diagnosis and focused on acute myeloid leukemia driver genes is helpful since the presence of pathogenic mutants (IDH1 p.Arg132His, SRSF2 p.Pro95Thr, WT1 p.Cys393Ter in this study) could represent additional risk factors or opportunities for targeted therapy. The gene discussed is SRSF2; the disease is acute myeloid leukemia.